Search
for
Sort by
Research 31–60 of 40
- An overview of current strategies and future prospects in drug repurposing in tuberculosis
- Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management
- Antiandrogens as Therapies for COVID-19: A Systematic Review
- The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19
- COVID-19: The question of genetic diversity and therapeutic intervention approaches
- Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies
- Transethosomes: A Comprehensive Review of Ultra-Deformable Vesicular Systems for Enhanced Transdermal Drug Delivery
- Drug Repurposing Patent Applications April–June 2021
- ZALCITABINE
- Manifestaciones dermatológicas asociadas a la gravedad de la infección por COVID-19. Estudio observacional transversal retrospectivo de 144 pacientes
- Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.
- Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
- Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).
- Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.
- Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
- Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 <i>in vitro</i> infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19
- An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females with mild-to-moderate COVID-19. The Pre-AndroCoV Female Trial
- An update of anti-viral treatment of COVID-19
- Feline Calicivirus: A comprehensive review
- Anthelmintic effect of Mentha spp. essential oils on Echinococcus granulosus protoscoleces and metacestodes
- COVID‐19, androgens, and androgenic alopecia
- Antihelminthic Drugs
- Effects of Post-Therapy Changes on the Level of Immunoglobulin M in Dogs with Dermatitis
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- The Evidence for Microbes in the Small Intestine as the Mechanism for Post-Finasteride Syndrome: Self-Reported Case Study
- The Evidence for Microbes in the Small Intestine as the Mechanism for Post-Finasteride Syndrome: Self-Reported Case Study
- The JAK/STAT signaling pathway: from bench to clinic
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
- Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
- Recent Advances in the Structural Design of Photosensitive Agent Formulations Using “Soft” Colloidal Nanocarriers